AstraZeneca demonstrates scientific leadership with compelling new data at ESC Congress 2023 on the interconnections across chronic diseases
AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August 2023, which includes data highlighting the opportunities for improved management in heart failure (HF), and AstraZeneca’s leadership across the interconnectedness of chronic diseases.
Among these abstracts will be sub-analyses from the DELIVER trial – a trial that has been pivotal in informing updates to medical guidelines. Notably, new late-breaking data from a pooled analysis of DELIVER and DAPA-HF trials assess the efficacy of Forxiga (dapagliflozin) versus placebo in HF patients whose eGFR levels fell below 25ml/min/1.73m2. The findings showed a marked elevation in the risks of CV outcomes in patients with deteriorating kidney function, further reinforcing the connection between heart failure and kidney disease. These patients appeared to benefit with continued treatment of Forxiga.1
New cardiopulmonary data from a sub-analysis of the DELIVER trial demonstrate the effects of Forxiga in patients with HF with preserved ejection fraction (pEF) and chronic obstructive pulmonary disease (COPD) - a common comorbidity that is associated with worse outcomes.2 In addition, findings from a multi-database cohort study, EXAcerbations of COPD and their OutcomeS in CardioVascular diseases (EXACOS-CV), illustrate increased COPD-driven cardiopulmonary risk including that of decompensated HF, acute coronary syndrome, arrhythmia, and ischemic stroke following a COPD exacerbation.3
Ruud Dobber, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, said: “We are proud of the continued practice-changing evidence from Forxiga trials, informing updates that recognise SGLT2 inhibitors as the first and only HF therapy with a class 1A recommendation. Our data presented at ESC 2023 reinforce how cardiorenal and cardiopulmonary diseases are complex and interconnected; diseases of one organ system negatively impacting another. It’s by understanding their interconnections that we’ll be able to detect, diagnose and treat people earlier and more effectively for better outcomes.”
Additional data being presented include:
Cardiorenal diseases affect hundreds of millions of people around the world.9 One in three people has multiple chronic conditions such as cardiovascular disease, type-2 diabetes, chronic kidney disease, or heart failure.10,11 Cardiorenal diseases account for four of the top 10 causes of death, globally.12 The economic cost of cardiorenal diseases is skyrocketing, (more than $28 trillion from 2023 to 2030) placing a heavy burden on societies, healthcare systems, and governments.13 These impacts are compounded by common comorbid conditions such as COPD, which is the third leading cause of death globally and significantly increases the risk of cardiovascular events.12,14
Complete overview of AstraZeneca abstracts at ESC 2023:
Increased risk of decompensated heart failure, acute coronary syndrome, arrhythmias and ischemic stroke following exacerbation of COPD: results from a multi-database cohort study
Session Title: Cardiovascular disease in primary care
Topic: Cardiovascular Disease in Primary Care
Date: 28 August
Location: Station 6
Impact on atrial remodelling of dapagliflozin in patients with heart failure (MODA TRIAL): baseline echo characteristics according to LVEF phenotypes
Session Title: Non-invasive imaging in heart failure: clinical insightsTopic: ImagingDate: 25 AugustTime: 08:15-09:00Location: Station 4
LATE BREAKER: Effects of dapagliflozin in patients with heart failure and deterioration of kidney function to eGFR less than 25ml/min/1.73m2: A participant-level pooled analysis of the DAPA-HF and DELIVER Trials
Session Title: Clinical trial updates on heart failure
Topic: Chronic Heart Failure
Date: 25 August
Presentation Time: 09:00
Location: Hub Rembrandt
Worse long-term prognosis in new onset HFpEF treated in HF clinics compared to HFrEF and HFmrEF patients, reflecting need for effective treatment in HFpEF. Results from the Stockholm PREFERS Study
Session Title: Heart failure outcomes: effects of phenotypes and comorbiditiesTopic: Pathophysiology and MechanismsDate: 25 AugustTime: 10:15-11:00Location: Station 3
LATE BREAKER: A prospective, observational multicentre registry of heart failure patients in Germany: preliminary results of the ongoing H2-registry
Session Title: Nuggets from international and large registries
Topic: Epidemiology, Prognosis, Outcome
Date: 25 August
Location: Station 3
Initiation, titration, and discontinuation - utilization of heart failure medicines in England (EVOLUTION HF UK)
PosterSession Title: Pharmacological therapy in heart failure 2Topic: PharmacotherapyDate: 25 AugustTime: 17:15-18:00Location: Station 3
Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction (DELIVER)
Session Title: Insights from recent HFpEF trials 1Topic: PharmacotherapyDate: 26 AugustTime: 15:30-16:30Presentation Time: 16:10Location: Science Box 2
Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
Session Title: Insights from recent HFpEF trials 1Topic: PharmacotherapyDate: 26 AugustTime: 15:30-16:30Presentation Time: 15:30Location: Science Box 2
Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Session Title: State-of-the art treatment of HFmrEF and HFpEF in 2023Topic: TreatmentDate: 27 AugustTime: 08:30-10:00Presentation Time: 09:24Location: Bucharest
Butt J H
Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial
PresentationSession Title: State-of-the-art treatment of HFmrEF and HfpEF in 2023Topic: TreatmentDate: 27 AugustTime: 08:30-10:00Presentation Time: 08:48Location: Bucharest - Lecture room
Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER
PresentationSession Title: State-of-the-art treatment of HFmrEF and HFpEF in 2023Topic: TreatmentDate: 27 AugustTime: 08:30-10:00Presentation Time: 09:42Location: Bucharest - Lecture room
Importance of early diagnosis and treatment of heart failure across the spectrum of ejection fraction
Session Title: Aspects of epidemiology, aetiology, and outcomes in heart failureTopic: Epidemiology, Prognosis, OutcomeDate: 27 AugustTime: 11:15-12:00Location: Station 3
LATE BREAKER: OPERA - AI reporting of handheld echocardiography in suspected heart failure
Session: Late-Breaking Science
Topic: European Society of Cardiology
Date: 27 August
Presentation Time: 14:26
Location: Bratislava, Amsterdam
Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER
Session Title: More insights into SGLT2i in heart failureTopic: PharmacotherapyDate: 28 AugustTime: 16:15-17:00Location: Station 3
Impact of worsening renal function in patients with incident heart failure across the spectrum of ejection fraction: a population-based longitudinal study
Session Title: Comorbidities in heart failure: bench to bedsideTopic: ComorbiditiesDate: 28 AugustTime: 12:15-13:00Location: Station 4
LATE BREAKER: DICTATE-AHF: Early initiation of dapagliflozin in acute heart failure
Session: Hot Line
Topic: European Society of Cardiology
Date: 28 August
LATE BREAKER: DAPA-MI – rationale and innovative design for a registry-based randomised clinical trial
Session: Registries on incident and prevalent heart failure
Date: 28 August
Location: Hub Mondrian - The Hub
van den Broek WWA
Impact of patient-reported frailty on cardiovascular outcomes in elderly patients with non-ST-elevation myocardial infarction
Session Title: Cardiovascular risk and advancing ageTopic: Cardiovascular Disease in the ElderlyDate: 25 AugustTime: 15:30-16:30Presentation Time: 16:10Location: Science Box 3
Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the RXFP1 relaxin receptor
Session Title: Experimental therapies for heart failureTopic: TreatmentDate: 28 AugustTime: 15:15-16:00Location: Station 3
ESC 2023 abstracts are available online.
AstraZeneca in CVRMCardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company's ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively.
AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
ContactsFor details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
1. Solomon D, et al. Effects of Dapagliflozin in Patients with Heart Failure and Deterioration of Kidney Function to eGFR Less Than 25ml/min/1.73m2: A Participant-Level Pooled Analysis of the DAPA-HF and DELIVER Trials. Presented at: ESC 2023, 25-28 August 2023, Amsterdam, Netherlands.
2. Butt J, et al. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease – an analysis of the DELIVER trial. Presented at: ESC 2023, 25-28 August 2023, Amsterdam, Netherlands.
3. Hawkins NM, et al. Increased risk of decompensated heart failure, acute coronary syndrome, arrythmias and ischemic stroke following exacerbation of COPD: results from a multi-database cohort study. Presented at: ESC 2023, 25-28 August 2023, Amsterdam, Netherlands.
4. James S, et al. Rationale and innovative design of the registry-based randomised DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. Presented at: ESC 2023, 25-28 August 2023, Amsterdam, Netherlands.
5. Lindenfeld J, et al. Efficacy and Safety of Dapagliflozin in Acute Heart Failure: DICTATE-AHF. Presented at: ESC 2023, 25-28 August 2023, Amsterdam, Netherlands.
6. Campbell R, et al. OPERA - AI - reporting of handheld echocardiography in suspected heart failure. Presented at: ESC 2023, 25-28 August 2023, Amsterdam, Netherlands.
7. Zhang R, et al. Initiation, titration, and discontinuation – utilization of heart failure medicines in England (EVOLUTION HF UK). Presented at: ESC 2023, 25-28 August 2023, Amsterdam, Netherlands.
8. Rosenmeier J, et al. Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the of the RXFP1 relaxin receptor. Presented at: ESC 2023, 25-28 August 2023, Amsterdam, Netherlands.
9. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22.
10. Mak KH, et al. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. Eur J Prev Cardiol. 2022;28(16):1795-806.
11. Einarson TR, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6. PMID: 29884191; PMCID: PMC5994068.
12. World Heart Organization [Internet]. The top 10 causes of death. [cited 2023 May 25]. Available From: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
13. AstraZeneca Data on File: REF-197704.
14. Khan S, et al. Comorbid Chronic Obstructive Pulmonary Disease and Heart Failure: Shared Risk Factors and Opportunities to Improve Outcomes. Ann Am Thorac Soc. 2022 Jun; 19(6): 897–899.
Download the Burden of Cardiovascular, Renal and Metabolic (CVRM) Diseases fact sheet